Prévention et prise en charge de la résistance antivirale dans l'hépatite B chronique [A primer on the management of antiviral resistance in chronic hepatitis B]


Autoria(s): Doerig C.; Sahli R.; Telenti A.; Moradpour D.
Data(s)

2009

Resumo

Treatment options for chronic hepatitis B have significantly expanded over the last decade. Six nucleoside or nucleotide analogs (NA) with activity against the hepatitis B virus are currently available. Prolonged NA treatment is required in many cases to maintain viral suppression, with an inherent risk of the development of antiviral resistance. The purpose of this concise review is to provide an introduction to the prevention, diagnosis and management of antiviral resistance in chronic hepatitis B.

Identificador

http://serval.unil.ch/?id=serval:BIB_FA928C2020B8

isbn:1660-9379

pmid:19271431

Idioma(s)

fr

Fonte

Revue Médicale Suisse, vol. 5, no. 187, pp. 203-208,

Palavras-Chave #Antiviral Agents; Drug Resistance, Viral; Hepatitis B, Chronic; Humans
Tipo

info:eu-repo/semantics/review

article